Slingshot members are tracking this event:

Halozyme Therapeutics (HALO) to commence Phase 1b/2 open label trial—under MORPHEUS platform—on PEG PH20, testing six tumors, including gastrointestinal, in 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
HALO Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Morpheus, Gastrointestinal Cancer, Tumors, Pegph20, Phase 1b/2